Randomized controlled trials (OXA+anti-EGFR vs OXA alone).

FOLFOX in COIN study: oxaliplatin 85 mg/m² on day 1, L-folinic acid 175 mg or D,L-folinic acid 350 mg on day 1, FU 400 mg/m² bolus and FU 2400 mg/m² infusion over 46 h. Every 2 weeks.

XELOX in COIN study: oxaliplatin 130 mg/m² on day 1, capecitabine 850 mg/m² twice a day on day 1 to 14. Every 3 weeks.

Cetuximab in COIN study: an initial dose of 400 mg/m² and thereafter 250 mg/m². Every week.

FLOX in NORDIC VII study: oxaliplatin 85 mg/m² on day 1, FU 500 mg/m² bolus +FA 60 mg/m² bolus on days 1 and 2. Every 2 weeks.

Cetuximab in NORDIC VII study: an initial dose of 400 mg/m² and thereafter 250 mg/m². Every week.

FOLFOX4 in OPUS study: oxaliplatin 85 mg/m² on day 1, leucovorin 200 mg/m² followed by FU 400 mg/m² bolus and 600 mg/m² 22-hour continuous infusion on days 1 and 2. Every 2 weeks.

Cetuximab in OPUS study: an initial dose of 400 mg/m² and thereafter 250 mg/m². Every week.

FOLFOX4 in PRIME study: oxaliplatin 85 mg/m² on day 1, leucovorin 200 mg/m² followed by FU 400 mg/m² bolus and 600 mg/m² 22-hour continuous infusion on days 1 and 2. Every 2 weeks.

Panitumumab in PRIME study: 6 mg/kg. Every 2 weeks.